What to Watch at Amgen, Merck, Pfizer, and Myriad Genetics This Morning

Amgen, Merck, Pfizer, and Myriad Genetics could loom large in health care headlines today. Here’s why.

Feb 5, 2014 at 9:16AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Good morning, fellow Foolish investors! Let's take a closer look at four stocks -- Amgen (NASDAQ:AMGN), Merck (NYSE:MRK), Pfizer (NYSE:PFE), and Myriad Genetics (NASDAQ:MYGN) -- which could all loom large in health care headlines this morning.

Amgen and Merck sign a collaboration for a new skin cancer treatment
Amgen and Merck just announced a new collaboration to evaluate an experimental melanoma (skin cancer) treatment combining Amgen's talimogene laherparepvec, an oncolytic immunotherapy, with MK-3475, Merck's investigational anti-PD-1 immunotherapy.

The combination treatment will be evaluated in a phase 1b/2 study of patients with mid- to late-stage melanoma. If the trial is successful, Amgen and Merck's combination therapy could go toe-to-toe against the dominant treatments in skin cancer, such as Roche's Zelboraf and Bristol-Myers Squibb's Yervoy.

Talimogene laherparepvec has shown promise in a phase 3 trial at Amgen as a monotherapy, and MK-3475 is being tested in phase 3 trials comparing the drug to Yervoy. The collaborative trial will be conducted in two parts, and will start in the fall of 2014:



Phase 1b

Determine the safety and tolerability of talimogene laherparepvec combined with MK-3475 in patients with previously untreated/unresected stage IIIb to IVM1a melanoma.

Phase 2

Evaluate the efficacy of the combination treatment versus MK-3475 as a monotherapy in patients with previous untreated/unresected stage IIIB to IVM1c melanoma.

Source: Company press release.

Peak sales estimates for Amgen and Merck's drugs fall in the same range as forecasts for Zelboraf and Yervoy -- between $500 million and $1.5 billion on a melanoma approval alone. However, sales of MK-3475 could eventually spike to $3 billion by 2020 if it is approved for other indications.

The approval of both drugs could help Amgen diversify its portfolio away from Enbrel, which accounted for 25% of its product sales last quarter. For Merck, it represents a way to offset the plunging sales of Singulair, which went off-patent in 2012, and lackluster sales of its diabetes drugs Januvia and Janumet.

Pfizer and Merck explore two new combination therapies using MK-3475
In addition to the new deal with Amgen, Merck also announced a collaboration with Pfizer to combine MK-3475 with two of Pfizer's cancer drugs:




MK-3475 and Inlyta

renal cell carcinoma (RCC)

Phase 1/2

MK-3475 and PF-2566

various anti-tumor responses

Phase 1

Source: Company press release.

The collaboration could help Pfizer grow its cancer portfolio, which is mainly fueled by sales of Xalkori and Inlyta. Last quarter, sales of Xalkori climbed 98% year over year to $89 million while sales of Inlyta soared 117% to $102 million. Although both drugs only account for tiny slivers of Pfizer's top line, analysts believe that Xalkori and Inlyta could eventually hit peak sales of $1.3 billion and $600 million, respectively.

Pfizer's palbociclib is another cancer treatment worth watching. Palbociclib is a targeted breast cancer drug which could treat a much larger population than current standards of care such as Roche's Herceptin (palbociclib could treat up to 60% of the advanced breast cancer population). If approved, palbociclib could generate peak sales of $1.9 billion.

Myriad Genetics to acquire Crescendo Bioscience
Last but not least, Myriad Genetics could do very well this morning after it agreed to purchase Crescendo Bioscience for $270 million in cash. Myriad's second quarter earnings report, which revealed a 43.7% year-over-year jump in its net profit, boosted shares even further. Revenue climbed 37% to $204.1 million. Both Myriad's top and bottom line growth surpassed analyst estimates.

Myriad is best known for its BRCA1 and BRCA2 diagnostic tests, which identify genes which are known to cause breast and ovarian cancer. Several of Myriad's key patents were invalidated last year by the Supreme Court, which has brought competitors such as Quest Diagnostics into the market, but so far Myriad still controls the lion's share of the market.

MYGN Chart

Source: Ycharts.

Acquiring Crescendo, which makes diagnostic tests for inflammatory and autoimmune diseases, will diversify Myriad's portfolio beyond breast cancer. Crescendo's main product, the Vectra DA, is a blood test for patients with rheumatoid arthritis, and generates roughly $10 million in sales per quarter.

The acquisition will dilute Myriad's earnings until 2016, after which it will become earnings accretive. Revenue, through organic and inorganic growth, will remain healthy -- the company now forecasts full-year sales between $740 million and $750 million, compared to its prior forecast of $700 million to $715 million.

Another top stock to watch this morning
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Quest Diagnostics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information